Jamshid Lotfi, MD
Neurology · Houston, TXNPI 1447447545
Payments from drug & device makers
Across 188 payments — averaging $32,126 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$3.1M
- Eli Lilly$1.3M
- Eisai Inc.$976K
- Novartis$261K
- American Regent$163K
- Adamas Pharmaceuticals, Inc.$153K
- plus $69K from 21 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 13 | $3,137,024 |
| Eli Lilly | 8 | $1,281,629 |
| Eisai Inc. | 46 | $975,765 |
| Novartis | 18 | $260,640 |
| American Regent | 7 | $162,542 |
| Adamas Pharmaceuticals, Inc. | 44 | $153,119 |
| Acadia Pharmaceuticals Inc | 7 | $29,246 |
| Alkermes, Inc. | 14 | $25,516 |
| AbbVie | 3 | $13,492 |
| EMD Serono, Inc. | 3 | $121 |
| UCB, Inc. | 2 | $73 |
| Supernus Pharmaceuticals, Inc. | 3 | $65 |
| SK Life Science, Inc. | 3 | $57 |
| Pfizer | 2 | $44 |
| Neurelis, Inc. | 1 | $40 |
| Amneal Pharmaceuticals LLC | 2 | $37 |
| Axsome Therapeutics, Inc. | 1 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Upsher-smith Laboratories LLC | 1 | $25 |
| Acorda Therapeutics, Inc | 1 | $25 |
| Livanova USA, Inc. | 1 | $21 |
| Sanofi | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
How this compares
$6,039,648 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Houston
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- John LindseyHouston$3.9M
- Joseph KassHouston$3.7M
- William OndoHouston$3.1M
- Vinay PuduvalliHouston$2.5M
- Erin Furr-StimmingHouston$2.1M
- Arjun TarakadHouston$2M
- Mazen DimachkieHouston$1.6M
- Melissa YuHouston$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.